Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| We remain confident in our ability to transform our PGS segment into a sustainably growing and profitable business and we are incredibly excited to help build toward a future of personalized preventative health |
| So there's a lot of great opportunities out there, and we continue to stay on top of this industry |
| Honestly, it's a very exciting time because it is – you've seen data transform all these other industries and you see it now coming fast and furious for the entire healthcare space and is particularly exciting for the world of drug discovery because drug discovery is so challenging and so expensive |
| But I am very inspired and excited about what we have been able to do with that translation of data into patients |
| And I'm very excited about 1473 and seeing the potential and the opportunities in patients |
| So we are very excited about the collaboration that we signed with – the partnership we signed with GSK, the opportunity to do more and for us to really be a leader in AI drug discovery |
| We can provide true value for them in the world of preventive care and we can also establish a truly viable membership business where our customers are returning value, and it is a solid and stable recurring business model for the company |
| Total Health – I think Total Health has an incredible potential |
| We have a very robust research database business, and we have a very robust therapeutics business |
| We have a very robust consumer business |
| Wrapping up, we are pleased with the company's strategic progress and improved operating discipline |
| I'd like to reiterate Anne's excitement about the future of Precision Healthcare 23andMe, and I'm proud of our ability to execute while maintaining cost discipline amid our shift towards a more sustainable operating profile |
| There is a growing recognition about the potential for data and AI and drug discovery, and we have an incredible asset that can accelerate and improve drug discovery for the industry |
| The excitement around AI and data opens up a tremendous opportunity for 23andMe as companies are establishing their data strategies |
| Importantly, this new collaboration is a sign of the significant value in the 23andMe database and the potential for continuous new insights and discoveries as we grow in size |
| We think the new site does a great job explaining how our team turns genetic insights into potential new therapies with a higher probability of success in the clinic and provides a great initial diligence resource for potential partners, collaborators and investors |
| As I look to 2024, I'm excited about the opportunities for 23andMe |
| I am extremely proud of the effort put forth by our team as we work towards creating a new future of healthcare powered by genetics |
| This program validates the power of the 23andMe database for identifying novel therapeutic targets and highlights the team's ability to develop molecules and advance them into the clinic |
| The study demonstrated that 23ME-00610 is well tolerated and shows promising preliminary efficacy in a number of patients with advanced solid malignancies |
| Given the current operating environment, we are being prudent in our planning and project prioritization, while remaining incredibly optimistic about the future of the company and our ability to help people access, understand and benefit from the human genome |
| And I think that's more and more what you can imagine us doing with Total Health is being able to help people not just get access to this information, but to leverage it and integrate it into their life |
| We also continue to refine and improve our genetic reports and insights |
| It has been a long journey and a very exciting journey, translating our data into novel therapeutics |
| We made meaningful strategic progress across our three businesses |
| This is an exciting step in our vision to bring accessible genetics-driven preventative care to millions of our U.S |
| So that has definitely been brought to our attention that there's a number of different businesses within this and what's the best way to make sure that we're maximizing value |
| So anything you can do that is going to make it more efficient and have a higher likelihood of success is going to really trickle down and have huge consequence, huge benefits for the entire world |
| It's really a two-pronged effort, but the most important being driving our growth in both membership and research businesses to have ongoing recurring revenue |
| But it is opportunities that we're considering about what's going to be the best way to make consumers successful in the therapeutics group |
| Statement |
|---|
| Revenue for the quarter was $45 million, representing a 33% decrease on another strong prior year comparable |
| This, plus an environment of macroeconomic and consumer uncertainty led to lower PGS kit sales volume |
| Our gross profit for the third quarter was $20 million, representing a 35% decrease over the same period in the prior year |
| The decrease in consumer revenue was driven primarily by lower sales volume as we entered the holiday promotional period with higher pricing than prior years |
| The increase in the third quarter net loss was driven mainly by the lower revenues and goodwill impairment charge mentioned previously |
| Similar to last quarter, the year-over-year decrease in revenue was primarily due to the conclusion of our exclusive discovery term under the GSK collaboration in July as well as lower consumer services revenue in our PGS Kit and telehealth businesses |
| We recognize this effort is likely to cause some uneven results in our business in the short-term, and we saw some of that effect in Q3 |
| These efforts were intended to increase product margin to improved average selling prices and advertising efficiency, which remain a core focus of the company, but resulted in lower-than-expected unit sales for the quarter as we believe the combination of higher prices and extended macro headwinds placed the temporary damper on demand for our products |
| PGS kit volumes were impacted in the quarter as we entered the holiday promotional period with firmer pricing discipline after raising prices for the first time since 2015 |
| As a reminder, the company's full-year fiscal 2024 guidance is based on the conservative approach, recognizing challenges in recent performance, continuing uncertainties in consumer sentiment, the macroeconomic environment and geopolitical conditions |
| The increase in the adjusted EBITDA deficit was primarily due to lower revenue, partially offset by lower personnel costs and lower R&D spend described previously |
| Total adjusted EBITDA deficit for the third quarter was $48 million compared to a $43 million deficit for the same period in the prior year |
| Looking at the bottom line, net loss for the quarter was $278 million compared to $92 million in the prior quarter |
| The decrease in Q3 gross profit was driven primarily by the decrease in research services revenue, while subscription revenue and improved telehealth margins following the August 2023 disposition of Lemonaid Health Limited in the UK helped to offset through continued margin accretion within their respective categories |
| Apologies for the background noise |
| I'm sorry if I missed that |
| I guess the market that I think does not – people want it and it doesn't really exist right now |
| A non-cash impairment charge for intangible assets in the prior period and lower therapeutics-related R&D spend due to significant IND-enabling activities also in the prior year |
Please consider a small donation if you think this website provides you with relevant information